SARO Outpaces Peers as Analysts Trim Targets Ahead of November Print

StandardAero gained 4.6% over the past week, making it the clear outperformer among its closest aerospace peers, where the median move was a loss of roughly 0.9%. GE slipped 0.7% on the week, TransDigm fell 1.1%, and HEICO gained just over 1%, while Boeing dropped 11.7%. SARO's 4.6% gain looks more like a relief bounce than a re-rating: the stock is still down around 20% year-to-date and trades at $22.42, well below the analyst mean target of $33.81.

The analyst community has spent the past few weeks trimming price targets without abandoning positive ratings. RBC Capital cut its target this week to $32 from $34 while holding Outperform, and CIBC followed on Monday with a move from $38 to $35, also keeping Outperformer. Susquehanna made a similar cut in early October, bringing its target to $34 from $37 and holding Positive. B of A Securities is the dissenting voice, carrying a Neutral with a $27 target. What that cluster of moves tells you is the Street still sees meaningful upside from current levels, but it is reducing its ambition as near-term estimates drift lower. The gap between the stock price and mean target is now above 50%.

The fundamental tension is a familiar one for engine MRO names. The bull case rests on contract durability: roughly 77% of revenue is tied to long-term agreements, and StandardAero holds the only independent LEAP CBSA license in the Americas, with management targeting around $1 billion in annual LEAP revenue by late 2029 or 2030. Against that, the bear case points to a 270 basis point decline in CRS margins to 26.3%, labor and ramp inefficiencies, and analysts modelling a roughly 1.5% CRS revenue decline in the current quarter alongside lower EBITDA assumptions. Pass-through revenue removal of $300 million to $400 million in FY2026 should mechanically lift margins, but that effect takes time to flow through. Valuation multiples are undemanding: EV/EBITDA is running at 9.5 times, and the earnings yield factor scores in the 67th percentile of the ORTEX universe. The short score, at 68.9, sits in the bottom 5% of the universe on that measure, reflecting the weight of short positioning that has built up this year.

Short interest tells a more nuanced story than the recent share-price strength might suggest. At 9% of free float, the position is meaningful but has actually edged lower over the past week, falling about 2.7% from mid-week peaks. The bigger move is the monthly trajectory: short interest has grown roughly 50% over the past 30 days, climbing from around 20 million shares in late September to just above 30 million now. Borrow conditions remain relaxed. Availability is at 268%, meaning lenders hold roughly two and a half times as many shares available as are currently borrowed, and cost to borrow is just 0.55%. There is no squeeze pressure here. The ORTEX short score of 68.9 reflects the scale of the short position more than any urgency in the borrow market.

Ownership is dominated by a handful of large holders whose recent moves are worth noting. Carlyle Group remains the largest shareholder at just over 25% of shares, down from 45.6% when it last amended its 13G filing in May, a steady distribution that has been a known technical overhang. T. Rowe Price added 1.17 million shares last quarter and now holds just under 16% of the company. Vanguard entities added a combined 5.6 million shares in the period. On the insider side, the only recent open-market activity is a small, unplanned sale of 780 shares by the Chief Legal Officer in mid-October. CEO Russell Wayne Ford's larger sales in July and August were all executed under a pre-arranged 10b5-1 plan and carry limited informational weight.

The earnings date is November 5. The last print, in August, sent the stock down 5.9% on the day and a further 12.5% over the following five sessions. That context matters for anyone positioning around the upcoming release: the revenue and margin assumptions going in have already been trimmed, which could reduce the gap between reported results and the Street's model, but the CRS margin trajectory and any update on LEAP ramp progress will be the numbers that move the stock.